Polydopamine conjugated SiO2 nanoparticles as potential drug carriers for melanoma treatment.

Silica nanoparticles (SiO2) are increasingly investigated for biomedical applications. Aim: This study aimed to analyze the potential use of a SiO2 nanoparticles coated with biocompatible polydopamine (SiO2@PDA) as a potential chemotherapeutic drug carrier. Materials & methods: SiO2 morphology and PDA adhesion was analyzed by dynamic light scattering, electron microscopy and nuclear magnetic resonance. Cytotoxicity studies and morphology analyses (immunofluorescence, scanning and transmission electron microscopy) were used to assess the cellular reaction to the SiO2@PDA nanoparticles and to identify a biocompatible (safe use) window. Results & conclusion: Concentrations above 10 μg/ml and up to 100 μg/ml SiO2@PDA showed the best biocompatibility on human melanoma cells at 24 h and represent a potential drug carrier template for targeted melanoma cancer treatment.

Citation

Ioana Mădălina Buhazi, Ioana-Georgeta Grosu, Xenia Filip, Anca Petran, Septimiu Cassian Tripon, Călin Gabriel Floare, Maria Suciu. Polydopamine conjugated SiO2 nanoparticles as potential drug carriers for melanoma treatment. Therapeutic delivery. 2023 Feb;14(2):157-173

Mesh Tags

Substances

PMID: 37158273

search → result